3 months ago
AstraZeneca (AZN) stock took a nosedive Monday amid reports it's mulling a megamerger with Bristol Myers Squibb (BMY).
The combined company would be worth roughly $400 billion, "making it one of the biggest pharmaceutical mergers in history," RBC Capital Markets ******* yst Trung Huynh said in a report. The Financial Times first reported the early merger talks. AstraZeneca declined to comment to Investor's Business Daily. Bristol Myers didn't immediately respond.
The deal would merge two oncology powerhouses, and likely trigger an antitrust review. Bristol Myers fills portfolio gaps in blood cancer, immunology, cardiovascular diseases and central nervous system conditions where AstraZeneca lacks scale today, Huynh said.
AstraZeneca stock tumbled 6.9% to 157.97. Shares are already trading below their 21-day, 50-day and 200-day moving averages. Bristol Myers Squibb stock, on the other hand, inched a fraction higher to 65.47. The stock ended the regular session in a buy zone that runs up to 66.03.
Given the size of the two companies, the deal would likely be mostly stock-based, resulting in Bristol Myers shareholders owning roughly a third of the combined company, William Blair ******* yst Matt Phipps said in a client note. He says $160 billion makes sense as a price tag for Bristol Myers Squibb.
#astrazeneca #huynh #combined
The combined company would be worth roughly $400 billion, "making it one of the biggest pharmaceutical mergers in history," RBC Capital Markets ******* yst Trung Huynh said in a report. The Financial Times first reported the early merger talks. AstraZeneca declined to comment to Investor's Business Daily. Bristol Myers didn't immediately respond.
The deal would merge two oncology powerhouses, and likely trigger an antitrust review. Bristol Myers fills portfolio gaps in blood cancer, immunology, cardiovascular diseases and central nervous system conditions where AstraZeneca lacks scale today, Huynh said.
AstraZeneca stock tumbled 6.9% to 157.97. Shares are already trading below their 21-day, 50-day and 200-day moving averages. Bristol Myers Squibb stock, on the other hand, inched a fraction higher to 65.47. The stock ended the regular session in a buy zone that runs up to 66.03.
Given the size of the two companies, the deal would likely be mostly stock-based, resulting in Bristol Myers shareholders owning roughly a third of the combined company, William Blair ******* yst Matt Phipps said in a client note. He says $160 billion makes sense as a price tag for Bristol Myers Squibb.
#astrazeneca #huynh #combined
4 months ago
Advanced Micro Devices, Inc. (NASDAQ:AMD) is one of the 10 Best Stocks to Buy in Glen Kacher's Light Street Portfolio.
On July 6, 2026, Advanced Micro Devices, Inc. (NASDAQ:AMD) revealed a collaboration with Micro Center, a computer parts retailer. Through the collaboration, the company initiated the global launch of Ryzen AI Halo, a compact system that can run AI models with up to 200 billion parameters locally. Jack Huynh, SVP and general manager, Computing and Graphics Group, Advanced Micro Devices, Inc. (NASDAQ:AMD) stated:
With Ryzen AI Halo now shipping, developers have a powerful new platform to build the next era of agentic AI – the performance for ambitious workloads, the memory for larger models and the flexibility to move from idea to implementation without compromise.
In a separate move, Wells Fargo raised the price target on Advanced Micro Devices, Inc. (NASDAQ:AMD) from $505 to $615 on June 30, 2026. The firm's ***** yst maintained an Overweight rating on the stock. Wells Fargo cited raised estimates for AMD, driven by strong EPYC server CPU demand in addition to pricing upside. The firm maintains data center GPU forecasts above the Street consensus, increasing the 2027 and 2028 EPS projections to $13.40 and $18.75. Representing a market value of $44,602,231, Advanced Micro Devices, Inc. (NASDAQ:AMD) accounts for 8.35% of Glen Kacher's Light Street Portfolio.
Founded in 1969, Advanced Micro Devices Inc. (NASDAQ:AMD) is a world-leading semiconductor company specializing in high-performance computing and graphics solutions. Based in California, the company is a formidable competitor in the AI accelerator market with its Instinct MI300 and newer series GPUs.
On July 6, 2026, Advanced Micro Devices, Inc. (NASDAQ:AMD) revealed a collaboration with Micro Center, a computer parts retailer. Through the collaboration, the company initiated the global launch of Ryzen AI Halo, a compact system that can run AI models with up to 200 billion parameters locally. Jack Huynh, SVP and general manager, Computing and Graphics Group, Advanced Micro Devices, Inc. (NASDAQ:AMD) stated:
With Ryzen AI Halo now shipping, developers have a powerful new platform to build the next era of agentic AI – the performance for ambitious workloads, the memory for larger models and the flexibility to move from idea to implementation without compromise.
In a separate move, Wells Fargo raised the price target on Advanced Micro Devices, Inc. (NASDAQ:AMD) from $505 to $615 on June 30, 2026. The firm's ***** yst maintained an Overweight rating on the stock. Wells Fargo cited raised estimates for AMD, driven by strong EPYC server CPU demand in addition to pricing upside. The firm maintains data center GPU forecasts above the Street consensus, increasing the 2027 and 2028 EPS projections to $13.40 and $18.75. Representing a market value of $44,602,231, Advanced Micro Devices, Inc. (NASDAQ:AMD) accounts for 8.35% of Glen Kacher's Light Street Portfolio.
Founded in 1969, Advanced Micro Devices Inc. (NASDAQ:AMD) is a world-leading semiconductor company specializing in high-performance computing and graphics solutions. Based in California, the company is a formidable competitor in the AI accelerator market with its Instinct MI300 and newer series GPUs.
